Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality

European Journal of Heart Failure

Volumn 10, Issue 4, 2008, Pages 388-395

  Frantz, S ^a   Stork S ^a   Michels, K ^a   Eigenthaler, M ^a   Ertl, G ^a   Bauersachs, J ^a   Angermann, C E ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Heart failure; Matrix metalloproteinase; Prognosis; Tissue inhibitor of metalloproteinases

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

AGED; BIOLOGICAL MARKERS; CARDIAC OUTPUT, LOW; CAUSE OF DEATH; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REFERENCE VALUES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41449108661     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.02.015     Document Type: Article

References (36)

1. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87 (2007) 1285-1342
2. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109 (2004) 2850-2856
3. Matsunaga T., Abe N., Kameda K., Hagii J., Fujita N., Onodera H., et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol 105 (2005) 203-208
4. Squire I.B., Evans J., Ng L.L., Loftus I.M., and Thompson M.M. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10 (2004) 328-333
5. Wagner D.R., Delagardelle C., Ernens I., Rouy D., Vaillant M., and Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 12 (2006) 66-72
6. Webb C.S., Bonnema D.D., Ahmed S.H., Leonardi A.H., McClure C.D., Clark L.L., et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114 (2006) 1020-1027
7. Tziakas D.N., Chalikias G.K., Hatzinikolaou E.I., Stakos D.A., Tentes I.K., Kortsaris A., et al. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 96 (2005) 31-34
8. George J., Patal S., Wexler D., Roth A., Sheps D., and Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150 (2005) 484-487
9. Tziakas D.N., Chalikias G.K., Papaioakeim M., Hatzinikolaou E.I., Stakos D.A., Tentes I.K., et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96 (2005) 1449-1451
10. Wilson E.M., Gunasinghe H.R., Coker M.L., Sprunger P., Lee-Jackson D., Bozkurt B., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8 (2002) 390-398
11. Jordan A., Roldan V., Garcia M., Monmeneu J., de Burgos F.G., Lip G.Y., et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med 262 (2007) 385-392
12. Creemers E.E., Davis J.N., Parkhurst A.M., Leenders P., Dowdy K.B., Hapke E., et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284 (2003) H364-H371
13. Cavusoglu E., Ruwende C., Chopra V., Yanamadala S., Eng C., Clark L.T., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 151 (2006) 1101 e1-8
14. Lubos E., Schnabel R., Rupprecht H.J., Bickel C., Messow C.M., Prigge S., et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 27 (2006) 150-156
15. Martos R., Baugh J., Ledwidge M., O'Loughlin C., Conlon C., Patle A., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115 (2007) 888-895
16. Tayebjee M.H., Nadar S., Blann A.D., Gareth Beevers D., MacFadyen R.J., and Lip G.Y. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17 (2004) 764-769
17. Noji Y., Shimizu M., Ino H., Higashikata T., Yamaguchi M., Nohara A., et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 68 (2004) 355-360
18. Kotlyar E., Vita J.A., Winter M.R., Awtry E.H., Siwik D.A., Keaney Jr. J.F., et al. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail 12 (2006) 122-127
19. Yan A.T., Yan R.T., Spinale F.G., Afzal R., Gunasinghe H.R., Arnold M., et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12 (2006) 514-519
20. Ahmed S.H., Clark L.L., Pennington W.R., Webb C.S., Bonnema D.D., Leonardi A.H., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 (2006) 2089-2096
21. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
22. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40 (2007) 119-123
23. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
24. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
25. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070
26. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
27. Li Y.Y., Feldman A.M., Sun Y., and McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98 (1998) 1728-1734
28. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
29. Li Y.Y., Feng Y., McTiernan C.F., Pei W., Moravec C.S., Wang P., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 (2001) 1147-1152
30. Tyagi S.C., Kumar S.G., Haas S.J., Reddy H.K., Voelker D.J., Hayden M.R., et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 28 (1996) 1415-1428
31. Siwik D.A., and Colucci W.S. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9 (2004) 43-51
32. Xu X.P., Meisel S.R., Ong J.M., Kaul S., Cercek B., Rajavashisth T.B., et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99 (1999) 993-998
33. Banfi C., Cavalca V., Veglia F., Brioschi M., Barcella S., Mussoni L., et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 26 (2005) 481-488
34. Ohtsuka T., Hamada M., Saeki H., Ogimoto A., Hara Y., Shigematsu Y., et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 91 (2003) 1024-1027 A8
35. Altieri P., Brunelli C., Garibaldi S., Nicolino A., Ubaldi S., Spallarossa P., et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33 (2003) 648-656
36. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-464